Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.

Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, Cosmopoulos K, Thomas MP, Kuranda M, Pickard MD, Liu R, Bandi S, Smith PG, Lightcap ES.

Mol Cancer Ther. 2014 Jun;13(6):1625-35. doi: 10.1158/1535-7163.MCT-13-0634. Epub 2014 Mar 26.

2.

Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.

Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24.

3.

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A.

Mol Cancer Ther. 2013 Oct;12(10):1958-67. doi: 10.1158/1535-7163.MCT-12-1028. Epub 2013 Aug 12.

4.

MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies.

Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, Chang HC, Chou CT, Hsu CH, Hsieh JT, Chang SC, Pu YS, Huang KH.

Cancer Lett. 2015 Jul 28;363(2):127-36. doi: 10.1016/j.canlet.2015.01.015. Epub 2015 Jan 20.

PMID:
25615422
5.

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, Grant S.

Blood. 2016 May 5;127(18):2219-30. doi: 10.1182/blood-2015-06-653717. Epub 2016 Feb 5.

6.

The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.

Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA, Maciejewski JP, Carew JS.

Clin Cancer Res. 2015 Jan 15;21(2):439-47. doi: 10.1158/1078-0432.CCR-14-1960. Epub 2014 Nov 11.

7.

The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.

Zhao L, Yue P, Lonial S, Khuri FR, Sun SY.

Mol Cancer Ther. 2011 Dec;10(12):2415-25. doi: 10.1158/1535-7163.MCT-11-0401. Epub 2011 Sep 13.

8.

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, Yu J, Qi H, Yu XJ, Wang P, Chu YW, Yang M, Hua ZC, Ying HQ, Hoffman RM, Jeong LS, Jia LJ.

Cell Death Dis. 2014 Feb 13;5:e1059. doi: 10.1038/cddis.2014.21.

9.

Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.

Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, Lightcap ES.

Mol Cell Proteomics. 2011 Nov;10(11):M111.009183. doi: 10.1074/mcp.M111.009183. Epub 2011 Aug 26.

11.

Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, Sun Y.

Cancer Res. 2012 Jan 1;72(1):282-93. doi: 10.1158/0008-5472.CAN-11-2866. Epub 2011 Nov 9.

12.

Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.

Paiva C, Godbersen JC, Berger A, Brown JR, Danilov AV.

Cell Death Dis. 2015 Jul 9;6:e1807. doi: 10.1038/cddis.2015.161.

13.

MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.

Guo ZP, Hu YC, Xie Y, Jin F, Song ZQ, Liu XD, Ma T, Zhou PK.

Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. doi: 10.1016/j.bbrc.2016.12.162. Epub 2016 Dec 26.

PMID:
28034751
14.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, Smith PG.

Cancer Cell. 2012 Mar 20;21(3):388-401. doi: 10.1016/j.ccr.2012.02.009.

15.

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.

Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, Hsu CH, Pu YS, Shi CS, Huang KH.

Sci Rep. 2015 Nov 23;5:16948. doi: 10.1038/srep16948.

16.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG.

Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.

17.

Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.

Yan ZH, Burkhardt A, Loke HK, Chen J, Xu Q, Brauer P, Ma J, Lin Y, Garcia K, Dick LR, Bembenek ME.

Anal Biochem. 2013 Aug 15;439(2):109-15. doi: 10.1016/j.ab.2013.04.016. Epub 2013 Apr 25.

PMID:
23624319
18.

NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.

Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A.

Cancer Res. 2010 Dec 15;70(24):10310-20. doi: 10.1158/0008-5472.CAN-10-2062.

19.

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.

20.

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS.

Mol Cancer Ther. 2012 Apr;11(4):942-51. doi: 10.1158/1535-7163.MCT-11-0563. Epub 2012 Jan 12.

Supplemental Content

Support Center